Revance Therapeutics SG&A Expense (TTM) Analysis

Revance Therapeutics Inc (RVNC)

2.39 -0.17 (-6.64%) USD | NASDAQ | Jun 26, 10:13

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2013. Upgrade now.

Date	Value
March 31, 2024	297.28M
December 31, 2023	290.29M
September 30, 2023	270.18M
June 30, 2023	267.19M
March 31, 2023	237.68M
December 31, 2022	219.70M
September 30, 2022	204.81M
June 30, 2022	191.84M
March 31, 2022	194.69M
December 31, 2021	198.82M
September 30, 2021	203.51M
June 30, 2021	199.25M
March 31, 2021	178.94M
December 31, 2020	151.85M
September 30, 2020	117.26M
June 30, 2020	86.24M
March 31, 2020	70.47M
December 31, 2019	62.40M
September 30, 2019	56.36M
June 30, 2019	54.02M
March 31, 2019	53.16M
December 31, 2018	53.86M

Date	Value
September 30, 2018	52.39M
June 30, 2018	47.38M
March 31, 2018	43.26M
December 31, 2017	37.40M
September 30, 2017	32.61M
June 30, 2017	30.96M
March 31, 2017	29.37M
December 31, 2016	29.08M
September 30, 2016	28.88M
June 30, 2016	27.20M
March 31, 2016	26.55M
December 31, 2015	25.09M
September 30, 2015	22.98M
June 30, 2015	22.45M
March 31, 2015	20.95M
December 31, 2014	19.04M
September 30, 2014	17.25M
June 30, 2014	14.10M
March 31, 2014	12.88M
December 31, 2013	11.01M
September 30, 2013	9.622M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

54.02M

Minimum

Jun 2019

297.28M

Maximum

Mar 2024

177.64M

Average

196.76M

Median

SG&A Expense (TTM) Benchmarks